
Sign up to save your podcasts
Or


Send us Fan Mail
This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes.
From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe built a direct-to-consumer model that reshaped public engagement with DNA. We break down the science behind SNP genotyping, the shift from ancestry testing to drug discovery partnerships with pharma giants like GSK, and the promise and limits of consumer-driven precision medicine.
We also dive into the SPAC-era hype cycle, regulatory and FDA battles, privacy controversies around genetic data ownership, and the deeper ethical question at the heart of the company: who actually owns your biology once it’s been digitized?
This is a story about genetics, identity, data, and the uneasy intersection of science and consumer tech.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#23andMe #Genetics #Biotech #DNA #Genomics #PrecisionMedicine #HealthcareInnovation #BioTech #Pharma #DataPrivacy #ConsumerGenomics #SPAC #DrugDiscovery #SciencePodcast #PetriDishPerspectives #Ancestry #DigitalHealth
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology.
From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufacturing, and the “picks-and-shovels” strategy behind biotech’s biggest breakthroughs. We also unpack the company’s role during COVID-19, its expansion into CDMO services, and why some of the most powerful companies in healthcare are often the ones nobody talks about.
This is the story of the invisible engine behind modern biology and the company behind the companies.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#ThermoFisher #Biotech #LifeSciences #Biotechnology #Pharma #DrugDevelopment #Genomics #Diagnostics #CDMO #HealthcareInnovation #PrecisionMedicine #Science #Biopharma #PetriDishPerspectives #LaboratoryScience #SyntheticBiology #ThermoFisherScientific
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine.
We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, and Roche helped transform Alnylam from a risky platform biotech into a genetic medicines powerhouse. We also break down the development of Onpattro, Amvuttra, and the broader future of programmable medicine.
This is the story of persistence, platform biology, and the rise of RNA therapeutics.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #Alnylam #RNAi #GeneticMedicine #Biopharma #RNAInterference #Onpattro #Amvuttra #RareDisease #DrugDevelopment #PrecisionMedicine #Biotechnology #HealthcareInnovation #Pharma #PetriDishPerspectives
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients.
But over time, it has evolved into something much bigger.
We unpack how the program actually works, why it’s become a financial cornerstone for many hospital systems, and the growing tension with pharmaceutical companies like Pfizer and Johnson & Johnson. From contract pharmacy battles to questions around transparency and patient benefit, the 340B ecosystem sits at the center of one of the most complex, and controversial, debates in healthcare economics.
Because 340B isn’t just about drug discounts.
It’s about who captures value in the healthcare system and who it’s really meant to serve.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#340B #HealthcarePolicy #Pharma #DrugPricing #HealthEconomics #Biotech #HealthcareInnovation #PetriDishPerspectives #USHealthcare #PolicyExplained
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026!
This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms like ADCs and radiopharmaceuticals, and a structural shift toward AI-native drug discovery and in-vivo genomic medicine.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #BiotechNews #PharmaNews
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
What if cancer treatment wasn’t a drug but a living, evolving system inside your body?
In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from treating disease to programming the immune system.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#CAR-T #CellTherapy #Biotech #Oncology #Immunotherapy #CRISPR #HealthcareInnovation #Pharma #BiotechPodcast #PetriDishPerspectives #PrecisionMedicine #CancerResearch #FutureOfMedicine
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology.
This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from the pioneering work of Jokichi Takamine and the early days of enzyme therapeutics, to the merger that unified biological extraction with synthetic chemistry, and ultimately to the company’s bold, high-stakes bet on antibody-drug conjugates (ADCs).
At the center of it all is Enhertu, the drug that shattered the traditional HER2 classification and redefined how we think about targeting cancer. We unpack how Daiichi Sankyo solved the ADC “linker problem,” engineered a platform with unmatched precision, and built a pipeline that’s now reshaping treatment across breast, lung, and gastric cancers.
We also explore the strategic partnerships with AstraZeneca and Merck & Co., and what they signal about Daiichi Sankyo’s position as a true platform leader in the ADC gold rush.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #DaiichiSankyo #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Enhertu #LifeSciences #BiotechPodcast #PetriDishPerspectives
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs).
From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoGen’s story is anything but linear. We explore how the company survived the “ADC dark ages,” built foundational technology through partnerships with giants like Genentech and Roche, and ultimately made the bold pivot from platform provider to full-fledged drug developer.
If you want to understand how long it really takes to build a platform technology, why being early can be both a curse and a competitive advantage, and how persistence shapes success in biotech, this episode is for you.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #ImmunoGen #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Biotechnology #CancerResearch #AbbVie #LifeSciences #BiotechPodcast #PetriDishPerspectives
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But the road to this exit wasn't paved with easy wins, it was forged in the wreckage of a "zombie" penny stock that almost didn't survive 2008.
We take you through the high-stakes gamble of the DeeP-C trial, the behavioral economics behind the "Little Blue Box," and the strategic brilliance of the Genomic Health merger. We explore how Kevin Conroy turned a struggling Madison startup into a global diagnostic standard by mastering the one thing most biotechs ignore: the clinical workflow.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectives #ExactSciences #AbbottLaboratories #BiotechStrategy #Oncology #Cologuard #LiquidBiopsy #PharmaNews #MAndA #CancerDetection #ScientificTranslator #Diagnostics #HealthTech #KevinConroy #BiotechPodcast
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
Send us Fan Mail
In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology.
We break down the leaders of this revolution, comparing the "TechBio" pioneers like Insilico and Recursion with the massive infrastructure bets currently being made by Big Pharma giants. From the rise of autonomous, "closed-loop" labs to significant improvements in target discovery and preclinical timelines, we analyze where the technology is delivering measurable wins and where the "dirty data" gap still holds the industry back.
Finally, we address the hard truths of this transition, including the recent wave of industry layoffs and the emergence of the "Scientific Translator" as the most vital role in the modern lab. We look ahead to a 2030 landscape defined by digital control arms and personalized medicine, offering essential lessons for any professional navigating the risks and rewards of an AI-integrated pipeline.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectives
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
From the publisher's feed
Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎
Stream new episodes every…
https://linktr.ee/maneadkhin
#biotech #pharma #healthcare #podcast #petridishperspectives